Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$87.29 USD
-0.38 (-0.43%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $87.32 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.29 USD
-0.38 (-0.43%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $87.32 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
HOLX vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
by Zacks Equity Research
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Edward Lifesciences (EW) for Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.
The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
by Zacks Equity Research
Salesforce, BP, The Southern, PayPal and Edwards Lifesciences are included in this Analyst Blog.
Top Analyst Reports for Salesforce, BP & Southern Co.
by Mark Vickery
Toda's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), BP p.l.c. (BP) and The Southern Company (SO).
ALC vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALC vs. EW: Which Stock Is the Better Value Option?
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.
Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Edwards Lifesciences (EW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Investing in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Explore how Edwards Lifesciences' (EW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.13% and 1.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
by Urmimala Biswas
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings
by Zacks Equity Research
Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
Is a Beat Likely for West Pharmaceutical (WST) in Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Unveiling Edwards Lifesciences (EW) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.
Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth
by Zacks Equity Research
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.